Erschienen in:
26.08.2021 | Original Article
Gastric MALT Lymphoma: A 8-Year Experience
verfasst von:
Maria Eduarda Couto, Isabel Oliveira, Nelson Domingues, Luísa Viterbo, Ângelo Martins, Ilídia Moreira, Ana Espírito Santo, Sérgio Chacim, Cláudia Moreira, Dulcineia Pereira, Rui Henrique, José Mariz
Erschienen in:
Indian Journal of Hematology and Blood Transfusion
|
Ausgabe 3/2022
Einloggen, um Zugang zu erhalten
Abstract
Gastric mucosa-associated lymphoid tissue non-Hodgkin lymphoma (gMALT NHL) is the second most common gastrointestinal lymphoma (50% of all gastric lymphomas), being closely associated with Helicobacter pylori infection, justifying that antibiotic therapy is effective in over 75% of all cases. This is a retrospective study analyzing all adult gMALT NHL cases diagnosed and treated in a single center for 8 years, focusing on demographic features, treatment outcomes, and survival analysis. Sixty patients with a median age of 61 years (53.3% female gender) were analyzed. Most of the cases had localized disease (66.7% were Lugano stage I) and had low IPI scores (median: 1). There was a high prevalence of Helicobacter pylori infection (68.3%). Nearly 97% of the cases received treatment for the disease, a median of one line; 55% of the patients treated endured complete response after first-line therapy (mostly antibiotics). Median overall survival time and median progression-free survival time were not reached. The mean follow-up time was 81.8 months (95% CI: [73.3–90.3]). Thirty-six patients (60%) achieved a 3-year follow-up time; the mortality rate was 15% at the end of the study. Age superior to 65 years and transformation into DLBCL were statistically significant negative prognostic markers for survival in this study (p = 0.006 and p = 0.033, respectively). Our study confirms that gMALT NHL is an indolent disease with long-term survival. Many patients, however, are exposed to several treatment lines along their disease course.